Article Contents ::
- 1 The Brand Name AZINTRA-3 Has Generic Salt :: Fluconazole
- 2 AZINTRA-3 Is From Company Intra Lab Priced :: Rs. N.I.
- 3 AZINTRA-3 have Fluconazole is comes under Sub class #N/A of Main Class #N/A
- 4 Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name AZINTRA-3 Has Generic Salt :: Fluconazole
AZINTRA-3 Is From Company Intra Lab Priced :: Rs. N.I.
AZINTRA-3 have Fluconazole is comes under Sub class #N/A of Main Class #N/A
Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
|Brand Name||Company / Manufacturers||Strength||Unit||Price / N.I.|
|AZINTRA-3||Intra Lab||150MG(1T),1G(1T),1G(2T)||N.I.||Rs. N.I.|
|Company Brand Name||Salt Combination||Main Medical Class||Sub Medical Class|
|From Intra Lab :: AZINTRA-3||Fluconazole||#N/A||#N/A|
Indications for Drugs ::
Cryptococcal meningitis, Candidiasis, Tinea pedis, Tinea cruris, Tinea corporis, Vaginal candidiasis, Onychomycosis, Coccidioidomycosis, Cryptococcosis, Histoplasmosis, Mucosal candidiasis, Candidal balanitis, Dermatophytosis
Drug Dose ::
Adult: PO Superficial mucosal candidiasis 50 mg/day, up to 100 mg/day. Treatment duration: 7-30 days depending on condition. Candidal balanitis; Vag candidiasis 150 mg as a single dose. Dermatophytosis; Pityriasis versicolor; Cutaneous candidiasis 50 mg/day, for up to 6 wk. Systemic candidiasis; Cryptococcal infections Initial: 400 mg, then 200-400 mg/day. Max: 800 mg/day in severe cases. Prevention of relapse after a primary course of antifungal treatment for acute cryptococcal infections in AIDS patients 100-200 mg/day. Prophylaxis of fungal infections in immunocompromised patients 50-400 mg/day. Child over 1 year – superficial candidal infections, 1-2 mg/kg daily; systemic candidiasis and cryptococcal infections (including meningitis) – 3-6 mg/kg daily (in serious life threatening infections up to 12 mg/kg daily has been given to children aged 5-13 years – max. 400 mg daily). Renal impairment: Haemodialysis patients: Usual dose given after each session. CrCl (ml/min) <50 and not receiving dialysis 50% of the usual dose. >50 Usual dose.
Drug Precautions ::
Renal or hepatic impairment. May prolong QT interval. Pregnancy, lactation.
Drug Side Effects ::
Nausea, abdominal pain, vomiting, diarrhoea, flatulence; elevated liver function values; headache; rash, exfoliative dermatitis. Rarely, angioedema, anaphylactic reactions and thrombocytopenia. Potentially Fatal: Hepatotoxicity; rarely anaphylaxis; Stevens-Johnson syndrome.
Pregnancy category ::
Drug Mode of Action ::
Fluconazole decreases ergosterol synthesis by interfering w/ cytochrome P450 activity, thus inhibiting cell membrane formation of susceptible fungi including B. dermatitidis, Candida spp., C. immitis, C. neoformans, Epidermophyton spp., H. capsulatum, Micosporum spp., Trichophyton spp.
Drug Interactions ::
May increase plasma concentrations of oral hypoglycaemics (e.g. tolbutamide, glyburide, glipizide), phenytoin, theophylline, tofacitinib, rifabutin. May increase prothrombin time w/ anticoagulants. May cause significant increase in ciclosporin levels in renal transplant patients w/ or w/o renal impairment. Rifampicin reduces fluconazole levels. May increase risk of nephrotoxicity w/ tacrolimus. May increase the effect of short-acting benzodiazepines (e.g. midazolam). Potentially Fatal: Increased risk of cardiac arrhythmias or QT prolongation w/ terfenadine, cisapride, astemizole, pimozide, quinidine, halofantrine and erythromycin.